Please assess the completion status of the following clinical trial:

Trial Title: Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Completed the open-label extension study (MVT-601-3003).~2. Is a responder: Has a menstrual blood loss of \< 80 mL AND at least a 50% reduction from the parent study Baseline based on the results of the alkaline hematin testing performed on the feminine products returned at the Week 48 visit of the extension study.~3. Is not expected to undergo gynecological surgery or ablation procedures for uterine fibroids within the study period~Exclusion Criteria:~1. Has undergone myomectomy, ultrasound-guided laparoscopic radiofrequency ablation, or any other surgical procedure for fibroids, uterine artery embolization, magnetic resonance guided focused ultrasound for fibroids, or endometrial ablation for abnormal uterine bleeding at any time during the Parent study or extension study.~2. Has a weight that exceeds the weight limit of the dual-energy x-ray absorptiometry (DXA) scanner~3. Has developed any contraindication to treatment with estradiol or norethindrone acetate~4. Is currently pregnant or lactating, or intends to become pregnant during the study period~5. Met a withdrawal criterion in the open-label extension (OLE) study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Relugolix plus E2/NETA (Type: EXPERIMENTAL): Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
- Placebo tablets and capsules (Type: PLACEBO_COMPARATOR): * Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~* Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns.

Based on this trial design, predict the completion outcome and termination type (if applicable).